| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 23,144 | 5,975 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 32,900 | 7,001 |
| Cash and cash equivalents at beginning of period | 135,418 | - |
| Cash and cash equivalents at end of period | 168,318 | - |
Editas Medicine, Inc. (EDIT)
Editas Medicine, Inc. (EDIT)